Who Can File a Dupixent Cancer Lawsuit?

National Dupixent cancer attorneys provide information on who qualifies to file a lawsuit

Patients who have been diagnosed with Cutaneous T-Cell Lymphoma (CTCL), including Mycosis Fungoides or Sezary Syndrome, after using Dupixent are now learning of the potential connection between the drug and delayed cancer diagnosis.

Recent dermatology and oncology reports have documented cases where Dupixent, a medication widely prescribed for eczema, dermatitis, asthma, and sinusitis, appeared to mask early CTCL symptoms, allowing the disease to progress undetected. Critics say a link between Dupixent and delayed CTCL recognition has been suspected for some time and question whether the drug's manufacturers did enough to understand and disclose Dupixent's risks.

If you or a loved one was diagnosed with CTCL after using Dupixent, you may be eligible to file a Dupixent cancer lawsuit. Our law firm offers free, confidential consultations to anyone who believes they may have a claim. Below, we outline the basic qualifications considered in each Dupixent cancer lawsuit.

• CTCL Diagnosis: Cutaneous T-Cell Lymphoma is a rare form of non-Hodgkin lymphoma that often resembles eczema in its earliest stages. Because Dupixent reduces inflammation and improves skin appearance, early CTCL may remain hidden for months or even years before being properly identified. Patients may require biopsies, oncology treatment, and long-term monitoring. In many cases, CTCL can progress to more advanced stages before diagnosis is finally made. If you or a family member was diagnosed with CTCL after using Dupixent, you may qualify to file a lawsuit.
• Exposure to Dupixent: Dupixent (dupilumab) is prescribed for eczema, dermatitis, asthma, and chronic sinusitis. Numerous published reports now indicate that Dupixent may mask early CTCL symptoms, contributing to delayed diagnosis. Individuals who used Dupixent for several months or longer before their CTCL diagnosis--especially those who experienced worsening patches, spreading lesions, or new nodules--may meet the criteria to file a claim.

If you believe you meet these qualifications, it is likely you qualify to file a Dupixent cancer lawsuit. There are multiple reasons to pursue a claim. First, Dupixent cancer attorneys believe individuals harmed by delayed CTCL diagnosis may be eligible for compensation for medical treatment, ongoing care, pain, emotional suffering, and financial loss. Equally important for many is the opportunity to hold a large pharmaceutical company accountable for failing to warn patients and providers about known risks.

If you have questions about your eligibility, our experienced attorneys are available to provide a free, no-obligation consultation. We are committed to helping individuals and families seek justice and compensation for the harm caused by Dupixent-related CTCL.

Our attorneys are ready to discuss your circumstances. To learn more about filing a Dupixent Cancer Lawsuit, please fill out the form on this page.